Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Skokie Swift Corporation has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner working within 1 distinct art unit. The examiner in charge of this 1 pending office action is HOPPE, EMMA RUTH, who is also designated as the busiest examiner for the portfolio with 1 busiest examiner pending office action under her review.
The prosecution profile for Skokie Swift Corporation is currently streamlined, as all activity is limited to 1 distinct examiner. Because the 1 pending office action is housed in 1 distinct art unit, the company only needs to navigate the specific requirements of that single unit. HOPPE, EMMA RUTH manages the 1 pending office action, making her the primary point of contact for the current Biotechnology & Pharmaceuticals filings.
This level of concentration, with 1 pending office action and 1 distinct examiner, suggests a focused patent strategy. The 1 distinct art unit involved will dictate the examination standards for the 1 pending office action. Practitioners should focus on the specific tendencies of HOPPE, EMMA RUTH, as she holds the 1 busiest examiner pending office action that constitutes the entire active portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPPE, EMMA RUTH | 1 | 40.0% | +58.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392191 | DNA EXTRACTION | HOPPE, EMMA RUTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392191 | DNA EXTRACTION | HOPPE, EMMA RUTH | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18392191 | DNA EXTRACTION | HOPPE, EMMA RUTH | 1683 | §103§112 | Non-Final OA | — | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSkokie Swift Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emma Ruth Hoppe has the most, with 1 of Skokie Swift Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
